Your session is about to expire
← Back to Search
Virus Therapy
IR103 REMUNE + AMPLIVAX 1.0 for HIV/AIDS (RAISE Trial)
Phase 3
Waitlist Available
Research Sponsored by Immune Response BioPharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 52 weeks
Awards & highlights
RAISE Trial Summary
The primary objective is to compare & evaluate between the treatment groups the changes in decline/reduction of HIV viral load changes in the Remune + Amplivax group vs the Amplivax placebo groups. Additional objectives include changes in WBC White Blood Cell counts & CD4+ & CD8+ T cell counts along with increased HIV immunity.
Eligible Conditions
- HIV/AIDS
RAISE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 52 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~52 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The primary objective is to compare & evaluate between the treatment groups the changes in HIV viral load at Week 52
Secondary outcome measures
The secondary objective is to evaluate & compare changes in CD4+ & CD8+ T cell counts between the treatment groups
The secondary objective is to evaluate & compare changes in WBC White Blood Cell counts between the treatment groups
RAISE Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: IR103 REMUNE + AMPLIVAX 1.0Experimental Treatment1 Intervention
IR103 Vaccine contain the same active component as REMUNE® (Inactivated HIV-1 Antigen Drug Substance at 10 μg/mL p24 dose), and have one dose of Amplivax™ (HYB2055) Adjuvant (1.0 mg) added before emulsification in Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
Group II: AMPLIVAX 1.0 + IFAPlacebo Group1 Intervention
AMPLIVAX 1.0 mg Amplivax™ (HYB2055) Adjuvant (1.0 mg) + IFA Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
Find a Location
Who is running the clinical trial?
Immune Response BioPharma, Inc.Lead Sponsor
4 Previous Clinical Trials
388 Total Patients Enrolled
Richard Bartholomew, PhDStudy DirectorImmune Response BioPharma, Inc.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger